Feb 9, 2023 5:00 pm EST Prospective, Multicenter Study Demonstrates That DecisionDx®-Melanoma Test Results Can Significantly Reduce the Number of Sentinel Lymph Node Biopsy (SLNB) Procedures Performed When Used Within the Context of Current Guidelines
Feb 7, 2023 5:00 pm EST Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023
Feb 1, 2023 5:00 pm EST Castle Biosciences Earns a Top Workplaces USA Award for the Second Consecutive Year
Jan 23, 2023 7:00 am EST Castle Biosciences’ Medical Director to Present at the Precision Medicine World Conference 2023
Jan 17, 2023 5:00 pm EST Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences’ Skin Cancer Test Portfolio
Jan 8, 2023 7:00 pm EST Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results
Nov 21, 2022 7:00 am EST Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical Laboratory
Nov 17, 2022 7:00 am EST Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results
Nov 15, 2022 7:00 am EST Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors
Nov 14, 2022 7:00 am EST Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive Year
